The estimated Net Worth of Christian Cabou is at least $7.43 Milion dollars as of 23 April 2013. Christian Cabou owns over 13,937 units of Illumina Inc stock worth over $7,426,137 and over the last 18 years Christian sold ILMN stock worth over $0.
Christian has made over 29 trades of the Illumina Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Christian exercised 13,937 units of ILMN stock worth $516,226 on 23 April 2013.
The largest trade Christian's ever made was exercising 90,500 units of Illumina Inc stock on 29 January 2013 worth over $1,974,710. On average, Christian trades about 9,553 units every 44 days since 2006. As of 23 April 2013 Christian still owns at least 59,490 units of Illumina Inc stock.
You can see the complete history of Christian Cabou stock trades at the bottom of the page.
Christian's mailing address filed with the SEC is 9885 TOWNE CENTRE DRIVE, , SAN DIEGO, CA, 92121-1975.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley oraz Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: